Document:

Prepared by MerrillDirect

Exhibit 10.5

Confidential Materials omitted
and filed separately with the Securities and Exchange Commission.

Asterisks denote omissions.

LICENSE, ASSIGNMENT AND SUPPLY
AGREEMENT

             THIS
LICENSE, ASSIGNMENT AND SUPPLY AGREEMENT (the "Agreement”) is effective as of February
13, 1997 (the "Effective Date"), by and between COULTER
CORPORATION (hereinafter "Coulter Corporation") and its wholly-owned
subsidiary COULTER INTERNATIONAL CORPORATION (hereinafter "CIC"), each having its
respective principal place of business at 11800 S.W. 147th Avenue, Miami,
Florida 33196, and COULTER CELLULAR THERAPIES, INC. (hereinafter "CCTI"), having its principal
place of business at 3000 Sand Hill Road, Building 3, Suite 255, Menlo Park,
California 94025. Coulter Corporation and its Affiliates (including, but not
limited to, CIC) shall be referred to collectively in this Agreement as
"Coulter".

WITNESSETH

             WHEREAS, Coulter owns or Controls certain Patent Property,
Contractual Rights, Regulatory Rights, Technical Know-How, Biotechnology Assets
and Equipment, all relating to the use of Dense Particles (as such terms are
defined below) for separating, treating and/or conditioning selected blood
cells or other particles in a biological fluid; and

             WHEREAS, CCTI has expressed an interest in acquiring and/or
licensing said Patent Property, Contractual Rights, Regulatory Rights,
Technical Know-How, Biotechnology Assets and Equipment from Coulter; and

             WHEREAS, Coulter is willing to transfer ownership and/or
license said Patent Property, Contractual Rights, Regulatory Rights, Technical
Know-How, Biotechnology Assets and Equipment to CCTI subject to the terms and
conditions contained herein;

             NOW,
THEREFORE, in consideration of the mutual covenants herein contained and intending
to be legally bound thereby, the parties hereto agree as follows:

1.          DEFINITIONS.

             1.1.       "Affiliate"
of a party
shall mean any corporation or other business entity controlled, controlling or
under common control with such party. For purposes of this section,
"control" shall mean direct or indirect beneficial ownership of at
least fifty percent (50%) of the voting securities of such corporation or other
business entity. Notwithstanding the foregoing, for the purposes of this
Agreement, neither Coulter Corporation nor CIC shall be deemed to be an
Affiliate of CCTI, and CCTI shall not be deemed to be an Affiliate of Coulter
Corporation or CIC.

             1.2.       "Biotechnology
Assets" shall mean all hybridomas owned or Controlled by Coulter as of the
Effective Date. Such hybridomas shall include, but not be limited to, those
capable of producing the monoclonal antibodies ("MABs") listed below.
The parties agree and acknowledge that: (1) the hybridomas which are capable of
producing the Dana-Farber MABs listed below are Controlled by Coulter pursuant
to one or more of the Dana-Farber License Agreements; and (2) the MABs marked
with an asterisk (*) are subject to the terms of the Ortho Settlement
Agreement. 

	Coulter MABs
	Dana-Farber MABs

	

	

	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	 	[**]
	 	[**]
	 	[**]
	 	[**]
	 	[**]
	 	[**]
	 	[**]

             1.3.       "CCTI Field" shall mean the
fields of (a) Therapeutic Applications using Dense Particle Cell Separation
Technology and (b) RUO Applications using Dense Particle Cell Separation
Technology.

             1.4.       "Contractual
Rights" shall mean Coulter's rights and obligations under the following
agreements:

             (a)         Research and Development Agreement between Coulter Corporation and University of Miami,
Diabetes Research Institute, dated December 29, 1995, as amended by a
Research and Development Agreement Amendment dated on or about January 29, 1997
(the "Miami Research Agreement"). Such rights include all of
Coulter's rights in U.S. Patent Application Serial No. [**], filed [**]
entitled [**] both (i) as a joint owner under such patent application and (ii)
all rights Coulter has to obtain an exclusive license from the University of
Miami under the foregoing patent application pursuant to Article 5 of the Miami
Research Agreement.

             (b)         Therapeutic Consulting Agreements:

                           (ii)        Between Coulter Corporation and Dr. Lee Nadler,
dated April 1, 1996.

                           (iii)       Between Coulter Corporation and Dr. Jerome Ritz,
dated April 1, 1996.

                           (iv)        Between Coulter Corporation and Dr. James Griffin,
dated April 1, 1996.

                           (v)         Between Coulter Corporation and Dr. John Gribben,
dated April 1, 1996.

                           (vi)        Between Coulter Corporation and Dr. Norma Kenyon,
dated April 1, 1996.

             (a)         Research Service Agreement between Coulter Corporation and McMaster University,
dated January 30, 1997 (the "McMaster Agreement").

             (b)         Agreement for Purchase of Goods and
Supplies between Novamet Specialty Products. Corporation and Coulter Corporation,
dated January 29, 1997 (the "Novamet Agreement").

             1.5.       "Control"
shall mean the
ability to grant the licenses or sublicenses herein or to make the assignments
or transfers set forth herein, as the case may be, without violating the terms
of any agreement or other arrangement with any third party.

             1.6.       "Dana-Farber
License Agreements" shall mean the following five agreements and one
acknowledgment letter, between Coulter Corporation (or its predecessor) and the
Dana-Farber Cancer Institute, Inc. (or its predecessor) (hereinafter,
"Dana-Farber"):

                           (i)          Agreement between Sidney Farber Cancer
Institute and Coulter Electronics, Inc,, dated July 23, 1981;

                           (ii)         Agreement between Dana-Farber Cancer
Institute and Coulter Electronics, Inc., dated March 1, 1983;

                           (iii)        Agreement between Dana-Farber Cancer
Institute and Coulter Immunology, Division of Coulter Corporation, dated April
28, 1983;

                           (iv)       Agreement between Dana-Farber Cancer
Institute and Coulter Immunology, Division of Coulter Corporation, dated
April 1, 1987;

                           (v)        Agreement between Coulter Corporation
and Dana-Farber Cancer Institute, dated April 1, 1994 (the "1994 Dana-Farber
Agreement"); and

                           (vi)       Acknowledgment Letter from Dana-Farber
Cancer Institute, dated February 4, 1997.

             1.7.       "Dense
Particle Cell Separation Technology" shall mean technology in which Dense Particles are
used to separate, treat and/or condition selected human or animal blood cells
or other particulate material in a biological fluid.

             1.8.       "Dense
Particles" shall mean particles having a density significantly greater than the
density of human blood cells or other human cellular material, whereby such
particles settle, under gravitational force, in a suspending medium at a rate
significantly faster than blood cells settle in the same medium.

             1.9.       "Diagnostic
Applications" shall mean applications for diagnosing or monitoring
a human or animal disease or condition.

             1.10.    "Equipment"
shall mean
instrumentation useful in the analysis of biological fluids, as described in
Section 2.8 hereof.

             1.11.    "Ortho
Settlement Agreement" shall mean that Settlement Agreement, dated March
31, 1992, among Johnson and Johnson, Ortho Diagnostics Systems, Inc. and Ortho
Pharmaceutical Corporation (collectively, "Ortho"), Coulter
Corporation, and Dana-Farber Cancer Institute, as amended by that certain
Amendment to Settlement Agreement, dated February 4, 1997 ("Amendment to
Settlement Agreement").

             1.12.    "Patent
Property" shall mean:

                           (a)         the U.S. PATENTS listed on Exhibit 1 and any and all
continuations, continuations-in-part and divisions thereof; as well as any
re-issuance and/or re-examination or any extension of the U.S. PATENTS listed
on Exhibit 1;

                           (b)         the U.S. PATENT APPLICATIONS listed on Exhibit 1 and
any and all continuations, continuations-in-part and divisions thereof;

                           (c)         any U.S. patents issuing on applications,
continuations, continuations-in-part and divisions described in clause (b) of
this paragraph;

                           (d)         any re-issuance and/or re-examination of the patents
described in clause (c) of this paragraph;

                           (e)         the CORRESPONDING FOREIGN PATENTS AND APPLICATIONS
listed on Exhibit 1 (and all continuations, continuations-in-part, divisions
and any foreign equivalents thereof) and any foreign patents issuing on such
applications, including any re-issuance, re-examination, and any foreign
equivalents thereof;

                           (f)         any other U.S. or foreign patent applications and
patents which claim as a priority date under 35 U.S.C. §119 or §120 one of the
filing dates of, or priority dates claimed in, those U.S. PATENTS and U.S.
PATENT APPLICATIONS listed on Exhibit 1;

                           (g)        the INVENTION DISCLOSURE listed on Exhibit 1, as well
as any U.S. and foreign patent applications containing such disclosures (and
all continuations, continuations-in-part and divisions thereof);

                           (h)        any U.S. and foreign patents issuing on
applications, continuations, continuations-in-part, divisions and foreign
equivalents thereof described in clauses (f) and (g), including any re-issued
and/or re-examined patents and foreign equivalents based thereon;

                           (i)         all patents and inventions to which Coulter obtained
rights and licenses pursuant to the Ortho Settlement Agreement; and

                           (j)         all patents and inventions to which Coulter obtained
rights and licenses pursuant to the Dana-Farber License Agreements or any
Additional Biotechnology Asset License Agreement (excluding any rights or
licenses set forth in Section 1.12(i)).

             1.13.    "Property"
shall mean the
Patent Property, Contractual Rights, Regulatory Rights, Technical Know-How,
Biotechnology Assets and Equipment.

             1.14.    "Regulatory
Rights" shall mean the following regulatory filings, filed by Coulter with the
United States Food and Drug Administration ("FDA"): the Pre-IDE
Meeting Briefing Document, dated May 15, 1996; the Investigational Device
Exemption Application for use of T8 Mab-DP, dated December 19, 1996; and the
Type II Drug Master File for T8 Mab-DP product, dated December 23, 1996.

             1.15.    "RUO
Applications" shall mean applications intended solely for
research purposes pertaining to Therapeutic Applications.

             1.16.    "Technical
Know-How" shall mean any technical knowledge owned or Controlled by Coulter and
related to the: (a) automation of the cell separation process using Dense
Particles; (b) the use of Dense Particles for protein purification; or (c) cell
separation using Dense Particles for therapeutic applications and research
purposes.

             1.17.    "Therapeutic
Applications" shall mean applications for preventing, treating or
mitigating a disease or condition in humans and animals.

             1.18.    "Additional
Biotechnology Asset License Agreement" shall mean any license agreement between Coulter and
a third party (other than the Ortho Settlement Agreement and the Dana-Farber
License Agreements) which (i) is in existence as of the Effective Date and
(ii) grants Coulter a license to one or more Biotechnology Assets.

2.          GRANTS.

             2.1.       Grant Related to Coulter-Owned Patent
Property and Biotechnology Assets.

                           2.1.1    Coulter hereby grants to CCTI a worldwide,
royalty-free, exclusive license under (i) the Patent Property described in
Section 1.12 (a) - (h) and (ii) the Biotechnology Assets owned by Coulter
(including those set forth in Section 1.2), to practice any and all methods,
and to make, have made, use, offer for sale, sell and import any and all
processes, apparatus and products which are covered by one or more claims in
said Patent Property or which contain one or more Biotechnology Assets (or an
MAB produced by such Biotechnology Asset) owned by Coulter. Such license is
limited to the CCTI Field. The foregoing grant shall be subject to the
provisions of Section 2.10 regarding distribution rights.

                           2.1.2    CCTI has the right to sublicense, sell or otherwise
transfer its rights described in Section 2.1.1 to any other entity.

             2.2.       Grant Related to Other Patent Property
and Other Biotechnology Assets.

                           2.2.1    Coulter hereby grants to CCTI a worldwide, royalty
bearing (but only to the extent set forth in Section 2.2.2), exclusive
sublicense under (i) the Patent Property described in Section 1.12(i) and (ii)
those Biotechnology Assets Controlled by Coulter pursuant to any of the Dana
Farber License Agreements or any Additional Biotechnology Asset License
Agreement, to practice any and all methods, and to make, have made, use, offer
for sale, sell and import any and all processes, apparatus and products which
are covered by one or more claims in said Patent Property or which contain one
or more such Biotechnology Assets (or an MAB produced by such Biotechnology
Asset). Such sublicense is limited to the CCTI Field. The foregoing grant shall
be subject to the provisions of Section 2.10 regarding distribution rights. It
is understood by the parties that the exclusive sublicense granted from Coulter
to CCTI pursuant to this Section 2.2.1 may be under a non-exclusive license
from the licensor to Coulter.

                           2.2.2    The royalty rate applicable to the sublicense
granted pursuant to Section 2.2.1 shall be equal to any amounts which Coulter
becomes obligated to pay to (i) Dana-Farber under the Dana Farber License
Agreements (including the amount by which Coulter's advanced royalty balance
with Dana-Farber is reduced) and (ii) any third party under any Additional
Biotechnology Asset License Agreement, as a result of sales by, CCTI pursuant
to the sublicense set forth in Section 2.2.1.

                           2.2.3    CCTI has the right to sublicense, sell or otherwise
transfer its rights described in Section 2.2.1 to any other entity, subject to
the same limitations that apply to the underlying license or sublicense.

             2.3.       Acknowledgment Regarding Ortho Patent
Rights.

                           2.3.1    The parties acknowledge and agree that, pursuant to
Section 5.1 of the Ortho Settlement Agreement, Coulter Corporation and its
"Affiliates" (as such term is defined in the Ortho Settlement
Agreement) have a worldwide, non-exclusive right and license under the
"Subject Patents" (as such term is defined in the Ortho Settlement
Agreement) to make, have made, use and sell certain "Research
Products" and "Therapeutic Products" (as such terms are defined
in the Ortho Settlement Agreement). The parties further acknowledge and agree
that, pursuant to the Amendment to Settlement Agreement, CCTI will be deemed to
be an "Affiliate" of Coulter Corporation for so long as Coulter
Corporation owns in excess of ten percent (10%) of the voting securities of
CCTI and certain other conditions, as set forth in Section 5.1A of the Ortho
Settlement Agreement, are met. Accordingly, the parties acknowledge that the
license of Patent Property described in Section 1.12(i) extends from Ortho to
CCTI (as an "Affiliate" of Coulter Corporation under the terms of the
Ortho Settlement Agreement) and Coulter Corporation hereby covenants:
(i) that it will not practice any rights it has to such Patent Property in
the CCTI Field during the term of this Agreement; and (ii) that it will
not permit any other Affiliate of Coulter to practice any rights Coulter and
its other Affiliates have to such Patent Property in the CCTI Field during the
term of this Agreement. The foregoing covenant shall be subject to the
provisions of Section 2.10 regarding distribution rights. As additional
consideration for the foregoing covenant, CCTI agrees to pay royalties to
Coulter to the extent set forth in Section 2.3.2.

                           2.3.2    The royalty rate applicable to the acknowledgment of
rights set forth in Section 2.3.1 shall be equal to any amounts which Coulter
becomes obligated to pay to Ortho as a result of sales by CCTI pursuant to the
Ortho Settlement Agreement.

                           2.3.3    CCTI has the right to sublicense, sell or otherwise
transfer its rights described in Section 2.3.1 to any other entity; provided,
however, that the parties agree and acknowledge that such sublicense, sale or
other transfer of those Patent Rights described in Section 1.12(i) which refer
to rights derived pursuant to Article 5 of the Ortho Settlement Agreement will
require the prior written consent of Ortho.

             2.4.       Grant Related to Technical Know-How. Coulter hereby grants to CCTI a worldwide,
royalty-free, exclusive-license or sublicense, as the case may be, under the
Technical Know-How to-practice any and all methods, and to make, have made,
use, offer for sale, sell and import any and all processes, apparatus and
products. Such license is limited to the CCTI Field. The license or sublicense
includes the right to sublicense to third parties subject to the same
limitations that apply to the underlying license or sublicense; provided,
however, that the foregoing grant is subject to the provisions of Section 2.10
relating to distribution rights. CCTI will use the same efforts to protect the
confidentiality of such Technical Know-How as it uses to protect the
confidentiality of its own technical know-how of like character.

             2.5.       Assignment Related to Contractual Rights.

                           2.5.1    Subject to the terms of this Agreement, Coulter
hereby assigns to CCTI Coulter's entire right and interest in and to the
Contractual Rights; provided, however,
any obligations incurred by Coulter prior to the Effective Date shall remain
with Coulter.

                           2.5.2    As regards the Miami Research Agreement, CCTI hereby
grants to Coulter Corporation, under rights obtained by CCTI pursuant to the
Miami Research Agreement, a worldwide, royalty bearing (but only to the extent
set forth in Section 2.5.2), exclusive sublicense to make, have made, use,
offer for sale, sell and import any and all processes, apparatus and products
(i) covered by the invention disclosed and claimed in U.S. Patent Application
No. [**], filed [**]; or (ii) which utilize any technical know-how derived
by CCTI under the Miami Research Agreement. The sublicense is limited to the
field of Diagnostic Applications and related research applications which are
used for commercializing the Diagnostic Applications. The sublicense granted
under this Section 2.5.2 includes the right to further sublicense to third
parties subject to the same limitations that apply to the underlying exclusive
sublicense. The royalty rate applicable to the sublicense described in this
Section 2.5.2 shall be equal to any amounts which CCTI becomes obligated to pay
the University of Miami as a result of sales by Coulter Corporation.

                           2.5.3    Within thirty (30) days of the Effective Date,
Coulter Corporation will arrange to have executed and filed with the U.S.
Patent and Trademark Office the assignment of its rights to U.S. Patent
Application No. [**], and any continuations, divisionals, and foreign
counterparts thereof, to CCTI.  CCTI
will further arrange, with Coulter's reasonable assistance, to have executed
and filed any other assignments necessary to perfect such rights.

                           2.5.4    As regards the McMaster Agreement, CCTI hereby
grants to Coulter Corporation, under any rights obtained by CCTI pursuant to
the McMaster Agreement, a worldwide, royalty-free, exclusive license (except
with respect to any rights granted by CCTI to McMaster University) to make,
have made, use, offer for sale, sell and import any and all processes,
apparatus and products which (i) are covered by any patents or
(ii) utilize any technical know-how resulting from research work performed
under and during the term of the McMaster Agreement. The license is limited to
the field of Diagnostic Applications and related research applications which
are used for commercializing the Diagnostic Applications. The license granted
pursuant to this Section 2.5.4 includes the right to further sublicense to
third parties subject to the same limitations that apply to the underlying
exclusive sublicense.

             2.6.       Assignment Related to Regulatory Rights. Coulter hereby assigns to CCTI its entire right and
interest in and to the Regulatory Rights. Coulter shall directly and promptly
inform the FDA in writing that all such rights and interests are transferred to
CCTI, and Coulter will have primary responsibility for responding to the FDA
pertaining to any questions the FDA may have regarding the assignment of such
Regulatory Rights.

             2.7.       Option Related to Equipment. During the 12 month period commencing on the Effective
Date, CCTI is hereby granted an option to purchase any or all of the following
Coulter-made instruments at Coulter's [**]:

                           (a)         Hematology Analyzers

                           (b)         Elite Flow Cytometer (Sorter)

                           (c)         XL Flow Cytometer (Analyzer)

                           (d)         Multi-Q-Prep Sample Mixer

CCTI may exercise such option upon 30
days written notice to Coulter Corporation. Should CCTI exercise such option,
the purchase price is due within 60 days of the exercise date.

             2.8.       Future Intellectual Property and
Biological Materials. During the term of this Agreement, as may be reasonably requested by
CCTI, the parties hereto will meet to discuss in good faith any U.S. or foreign
patents or patent applications, any know-how and any biological materials which
are owned or Controlled by Coulter at the time of such meeting, which are not
already included in the Property and which may be necessary or useful to CCTI
in developing and commercializing products or processes in the CCTI Field. Each
of the foregoing patents, patent applications, know-how and biological
materials shall be deemed to be a "New Property Right."

                           2.8.1    In the event that (i) a New Property Right is
first owned or Controlled by Coulter at any time during which Coulter owns or
controls at least fifty percent (50%) of the voting securities of CCTI and
(ii) CCTI indicates to Coulter that it is interested in obtaining a
license or sublicense to such New Property Right in the CCTI Field, the parties
will promptly modify this Agreement to add such New Property Right to the
definition of Patent Property, Technical Know-How or Biotechnology Assets
(whichever is applicable) and to make such New Property Right subject to the
license grants contained in Article 2.

                           2.8.2    In the event that (i) a New Property Right is
first owned or Controlled by Coulter at any time during which Coulter owns or
controls at least ten percent (10%) but less than fifty percent (50%) of the
voting securities of CCTI and (ii) CCTI indicates to Coulter that it is
interested in obtaining a license or sublicense to such New Property Right in
the CCTI Field, the parties will promptly meet to negotiate in good faith an
agreement pursuant to which Coulter will grant an exclusive license or
sublicense, as appropriate, to CCTI to such New Property Right, upon
commercially reasonable terms to be agreed to by Coulter and CCTI.

             2.9.       Offers to Coulter Personnel. Coulter agrees to allow CCTI to provide offers of
employment to those Coulter personnel who CCTI believes are necessary or useful
to achieve the scientific objectives of CCTI.

             2.10.    Distribution Rights for RUO Applications. In the event CCTI intends to distribute or have
distributed RUO Applications for any products sold under the license set forth
in Sections 2.1-2.3, CCTI shall provide written notice to Coulter Corporation
of such intention; provided, that
such notice shall be delivered in the manner specified in Section 2.10, with an
additional notice to Coulter's Director of Business Development at the same
address as Coulter. Such notice shall describe the RUO Applications markets to
which CCTI intends to distribute. Within [**] days of receipt of such notice,
Coulter Corporation shall provide written notice to CCTI indicating whether it
is interested in distributing such products to such markets. If Coulter
Corporation indicates it is not interested in undertaking such distribution or
has not provided written notice to CCTI within such [**] day period, CCTI shall
be free to distribute such products to such RUO Applications markets either
itself or through a third party. If Coulter Corporation provides timely written
notice of its interest in undertaking such distribution, then CCTI and Coulter
Corporation will negotiate in good faith for a period of [**] to enter into a
commercially reasonable distribution agreement for such RUO Applications
markets. In the event the parties are unable, after good faith negotiations, to
agree on a distribution arrangement within such [**] period, CCTI shall be free
to distribute such products to such RUO Applications markets either itself or
through a third party; provided, however,
that CCTI may not enter into an agreement for distribution of RUO Applications
described in this Section 2.10 on terms less favorable to CCTI than those
offered by Coulter during such [**] good faith negotiation period.

3.          TRANSFER OF
HYBRIDOMAS.

             3.1.       Provision of Biotechnology Assets. Coulter shall provide CCTI with sufficient
quantities (up to [**] vials) of each of those Biotechnology Assets (including,
but not limited to, those Biotechnology Assets which are useful in producing
the Coulter MABs and Dana-Farber MABs listed in Section 1.2) which CCTI deems
to be necessary and useful in developing and/or commercializing Dense Particle
Cell Separation Technology, in order for CCTI to prepare a manufacturing lot of
each such Biotechnology Asset. Such Biotechnology Assets shall be provided from
the Manufacturers' Working Cell Bank ("MWCB"), located at Coulter
within [**] of a written request by CCTI.

             3.2.       Delivery to CCTI. Deliveries shall be made from Coulter's facility and
shall be shipped by a carrier selected by CCTI to any address as directed by
CCTI in writing. Biotechnology Assets will be shipped by Coulter freight
collect, or if prepaid, such freight will be subsequently billed to CCTI.  If requested by CCTI, Coulter will insure
the shipments against damage to or loss of the Biotechnology Assets and will
subsequently bill CCTI for such shipping insurance. CCTI will reimburse Coulter
for shipping and insurance expenses, if any, within [**] days after the date of
its receipt of such invoices.

             3.3.       Title. Title to Biotechnology Assets shall pass to CCTI
when the Biotechnology Assets are delivered to a carrier pursuant to Section
3.2.

             3.4.       Acceptance. CCTI shall inspect all Biotechnology Asset shipments
promptly upon receipt thereof at the shipping destination and may reject any
Biotechnology Assets which are damaged or otherwise unusable as intended by
CCTL Biotechnology Assets not rejected by written notification to Coulter
within [**] days after receipt shall be deemed to have been accepted, except
for latent defects which are not reasonably detectable at the time of
acceptance. Rejected Biotechnology Assets shall be destroyed by CCTI within
[**] days after rejection. Upon receipt of written notice that goods have been
properly rejected, Coulter shall promptly replace the rejected Biotechnology
Assets at Coulter's expense. For properly rejected Biotechnology Assets,
Coulter will prepay transportation and insurance charges for shipping any
replaced Biotechnology Assets back to CCTL.

             3.5.       New Manufacturers' Working Cell Banks.

                           3.5.1    If CCTI's requirement for a given Biotechnology
Asset is such that Coulter is required to prepare and certify a new MWCB for
such Biotechnology Asset in order to provide such Biotechnology Asset to CCTI,
Coulter will use commercially reasonable efforts to establish such new MWCB in
such time as to allow it to meet CCTI's requirements, subject to CCTI's
obligation to pay Coulter for such new MWCB as set forth in Section 4.2. 1.

                           3.5.2    In the event that Coulter, despite using
commercially reasonable efforts, is not able to establish a working cell bank
for a given hybridoma cell line in such time to meet CCTI's requirements for a
given Biotechnology Asset, Coulter will provide to CCTI in a timely manner the
hybridoma cell line capable of producing the required monoclonal antibodies. In
the event that Coulter provides a hybridoma cell line pursuant to this Section
3.5.2, no amounts shall then be payable to Coulter under Section 4.2 for such
hybridoma cell line. In the event that this Section 3.5.2 is applicable,
Coulter will cooperate with CCTI in enabling CCTI to establish its own working
cell bank for such hybridoma cell line.

             3.6.       Use of Biotechnology Assets. CCTI agrees that it will not produce NIABs from the
Biotechnology Assets except for those to be used in the development and/or
commercialization of processes and products in the CCTI Field. CCTI will use
its efforts to protect the intellectual property relating to the Biotechnology
Assets which are at least as protective as those used by CCTI to protect its
own biotechnology assets of comparable value. CCTI will keep a record of the
distribution and location history of each hybridoma and its progeny and
derivatives for reference by Coulter, if needed.

4.          CONSIDERATION.

             4.1.       Stock In CCTI. As consideration for the grants and other rights set
forth in this Agreement, CCTI shall convey to Coulter Corporation the ownership
of Seven Million, Five Hundred Thousand (7,500,000) shares of CCTI's Series A
Preferred Stock, pursuant to that certain Series A Preferred Stock Purchase
Agreement, dated as of February 13, 1997, by and among Coulter Corporation,
CCTI and certain other parties.

             4.2.       Cash Payments.

                           4.2.1    In addition to the consideration described in
Section 4. 1, CCTI shall pay Coulter Corporation the sum of [**] Dollars
($[**]) per shipment of hybridoma from a MWCB (typically [**] vials) to CCTI or
its designee, pursuant to Section 3. 1, to offset Coulter's administrative,
shipping and handling costs.

                           4.2.2    Further, if Coulter is required to prepare and
certify a new MWCB pursuant to the provisions of Section 3.5. 1, then CCTI
shall pay Coulter Corporation the sum of [**] Dollars ($[**]) per each new
MWCB, upon receipt of documentation from Coulter that such new MWCB is in fact
capable of producing the requested Biotechnology Asset.

5.          COULTER
REPRESENTATIONS AND WARRANTIES.

             Coulter
Corporation and CIC each represent and warrant to CCTI that the statements
contained in this Article 5 are true, accurate, complete and not misleading in
any material respect.

             5.1.       Organization and Good Standing. Coulter Corporation is a corporation, legally and
validly incorporated, organized, existing and in good standing under the laws
of the State of Delaware. CIC is a corporation, legally and validly
incorporated, organized, existing and in good standing under the laws of the
State of Florida.

             5.2.       Authority Regarding this Agreement.

                           5.2.1    Coulter Corporation and CIC each has the complete
and unrestricted right, power, authority and capacity to: (a) execute and
deliver this Agreement; (b) subject to the provisions of the Ortho
Settlement Agreement and the Dana Farber License Agreements, sell, transfer,
assign, license or sublicense, as applicable, the Property to CCTI; and
(c) carry out and perform Coulter Corporation's and CIC's other
obligations pursuant to this Agreement; provided,
however, to the extent the representation and warranty set forth in
clause (b) of this sentence applies to a given Biotechnology Asset which was
acquired by Coulter pursuant to an Additional Biotechnology Asset License
Agreement, such representation and warranty shall be subject to any limitations
on Coulter contained in such third-party agreement.

                           5.2.2    No further corporate or shareholder approvals or
proceedings are necessary on the part of Coulter Corporation or CIC to
authorize this Agreement or any of the transactions contemplated hereby. The
execution, delivery and performance of this Agreement by Coulter Corporation or
CIC do not require notice to, or consent or approval from, any governmental
body or other regulatory authority.

                           5.2.3    This Agreement has been duly and validly executed
and delivered by Coulter Corporation and CIC, is a legal, valid and binding
obligation of Coulter Corporation and CIC, enforceable in accordance with its
terms.

             5.3.       Property.

                           5.3.1    Coulter owns or Controls all Property.

                           5.3.2    No claims with respect to the Property have been
asserted nor, to the best of Coulter's knowledge, are any claims with respect
to the Property threatened, by any person, nor is there any valid grounds, to
the best of Coulter's knowledge, for any bona fide claims challenging the
ownership, validity, enforceability or effectiveness of any of the Property. To
the best of Coulter's knowledge, there is no material unauthorized use,
infringement or misappropriation of any of the Property by any third party,
including any employee or former employee of Coulter.

                           5.3.3    Neither Coulter Corporation nor CIC has been sued or
charged as a defendant in any claim, suit, action or proceeding which involves
a claim of infringement of any patents or violation of any trade secret or
other proprietary right of any third party with respect to the Property, and to
the best of Coulter's knowledge, there is not any infringement liability with
respect to, or infringement or violation by, Coulter of any patent, trade
secret or other proprietary right of another. The Property is not subject to
any outstanding order, judgment, decree, stipulation or agreement restricting
in any manner the sale, assignment, licensing or sublicensing thereof by
Coulter. No inequitable conduct or fraud has occurred during the prosecution of
any of the patents or patent applications with respect to the Property.

                           5.3.4    All patents and patent applications owned or
Controlled by Coulter as of the Effective Date which contain claims to Dense
Particle Cell Separation Technology are set forth on Exhibit 1 attached hereto.

             5.4.       No Conflict. The execution, delivery and-performance of this
Agreement and the consummation of the transactions specified herein hereby will
not: (a) breach or constitute grounds for declaration or occurrence of a
default under any agreement or other document to which Coulter is a party or by
which the Property may be bound or affected; (b) violate any law,
regulation, order, judgment or decree of any court or governmental agency; or
(c) result in the creation or imposition of any lien on the Property.
Reduction of Coulter Corporation's equity ownership of CCTI below fifty percent
(50%) of CCTI's outstanding securities will not cause Coulter to be in breach
or default of any agreement. Notwithstanding the preceding sentence, it is
understood by the parties that pursuant to the Amendment to Settlement
Agreement, in the event Coulter Corporation's ownership interest in CCTI's
voting securities falls to ten percent (10%) or lower, CCTI will no longer have
the license set forth in Section 2.3. Except as restricted by the terms of the
Ortho Settlement Agreement, the Dana Farber License Agreements, and any
Additional Biotechnology Asset License Agreement, sublicense, assignment or
other transfer by CCTI of any of the Property owned or Controlled by Coulter as
of the Effective Date will not cause Coulter or CCTI to be in breach or default
of any agreement to which Coulter is a party or is otherwise bound, nor will
any such sublicense, assignment or transfer require Coulter or CCTI to obtain
any waiver or approval of any third party.

             5.5.       Litigation. There is no litigation, investigation, arbitration
or other proceeding pending or threatened against or adversely affecting the
Property, or Coulter Corporation's and CIC's right and ability to consummate
the transactions specified herein by this Agreement; nor does Coulter know or
have reason to know of any basis for the same.

             5.6.       Compliance with Laws. Coulter Corporation and CIC are in compliance with
all statutes, laws, rules and regulations with respect to or affecting the
ownership and use of the Property.

             5.7.       No Bankruptcy Proceedings. No petition, decree or order has been filed by or
against Coulter Corporation or CIC under any bankruptcy, insolvency or similar
laws, and no receiver, liquidator, trustee, custodian or other officer has been
appointed with respect to Coulter Corporation or CIC, or their assets and
liabilities pursuant to any such law. Coulter Corporation and CIC have no
reason to expect that any such actions will take place.

             5.8.       Coulter Agreements. Neither Coulter Corporation nor CIC is in material
breach of any of the agreements described in Sections 1.4, 1.6, and 1.11 or the
Additional Biotechnology Asset License Agreements (collectively, the
"Coulter Agreements"). There are no grounds for any party to any of
the Coulter Agreements to terminate such agreements and Coulter has not
received a notice of default with respect to any of the Coulter Agreements.

             5.9.       No Other Agreements. Except for the Coulter Agreements, neither Coulter
Corporation nor CIC, nor any Affiliate of Coulter Corporation or CIC, has
entered into any other agreements reasonably necessary to CCTI's practice of
the Dense Particle Cell Separation Technology or use of the Biotechnology
Assets in the CCTI Field. If any other agreement comes to Coulter's attention
relating to the Dense Particle Cell Separation Technology, Coulter shall
provide a copy to CCTI and will cooperate with CCTI to assign, license,
sublicense or transfer rights under such agreement as applicable.

             5.10.    No Regulatory Issues with Respect to Dense
Particle Cell Separation Technology. Coulter is not aware of any regulatory rulings or
inquiries which would have a material adverse effect on the ability of CCTI to
develop and commercialize Dense Particle Cell Separation Technology under the
Property.

             5.11.    Limitation on Warranties. Nothing in this agreement shall be construed as a
warranty or representation by Coulter that anything made, used, sold, or
otherwise disposed of by CCTI under any license or sublicense granted in this
agreement is or will be free from infringement of patents of third parties; provided, however, Coulter represents that
it is not aware of any such infringement as of the Effective Date. Coulter
makes no warranty, express or implied, concerning the fitness for any particular
purpose of any products licensed or the property rights licensed to CCTI.

6.          CCTI
REPRESENTATIONS AND WARRANTIES.

             CCTI
hereby represents and warrants that the statements contained in this Article 6
are true, accurate, complete and not misleading in any material respect.

             6.1.       Organization and Good Standing. CCTI is a corporation, legally and validly
incorporated, organized, existing and in good standing under the laws of the
State of Delaware.

             6.2.       Authority Regarding this Agreement.

                           6.2.1    CCTI has the complete and unrestricted right, power,
authority and capacity to: (a) execute and deliver this Agreement; and (b)
carry out and perform CCTI's obligations pursuant to this Agreement.

                           6.2.2    No further corporate or shareholder approvals or
proceedings are necessary on the part of CCTI to authorize this Agreement or
any of the transactions contemplated hereby. The execution, delivery and
performance of this Agreement by CCTI does not require notice to, or consent or
approval from, any governmental body or other regulatory authority.

                           6.2.3    This Agreement has been duly and validly executed
and delivered by CCTI and is a legal, valid and binding obligation of CCTI,
enforceable in accordance with its terms.

7.          PATENT
PROPERTY.

             7.1.       Prosecution and Maintenance.  Coulter shall, at its own expense, have the first
right to (i) file and prosecute all patent applications contained within the
Patent Property and (ii) maintain all patents contained within the Patent
Property. In the event that Coulter decides not to proceed with prosecuting a
patent application for, or maintaining a patent on, an invention for which it
is responsible under this Section 7.1, it shall give CCTI [**] days notice
before any relevant deadline and transmit all information reasonable and appropriate
relating to such patent application or patent, and CCTI shall have the right to
pursue, at its own expense, prosecution of such application for, or maintenance
of, such patent.

             7.2.       Infringement of Patent Property by Third
Parties.

                           (a)         Notice.  Each party shall promptly notify the other in writing of any alleged or
threatened infringement of the Patent Property of which it becomes aware and
which may adversely impact the rights of CCTI hereunder.

                           (b)         Enforcement Action.  In the event that the parties become aware of any
alleged or threatened infringement of the Patent Property, Coulter shall have
the right, but not the obligation, to take appropriate action against any
person or entity directly or contributorily infringing such Patent Property. In
the event Coulter fails to institute an infringement suit or take other
reasonable action in response to such infringement within [**] days, CCTI shall
have the right, but not the obligation upon [**] days notice to Coulter, to
institute such suit or take other appropriate action in its own name; provided
however, that if necessary, Coulter agrees to be joined as a party plaintiff.
Regardless of which party brings such enforcement action, the other parties
hereby agree to cooperate reasonably in any such effort. The parties not
bringing the action shall have the right to participate in such action at their
own expense with their own counsel and any recovery obtained by settlement or
otherwise shall be disbursed as follows: each party shall first recover any
reasonable expenses incurred in such action (including counsel fees).
Thereafter, the parties shall share any remaining recovery in accordance with
their economic interests in the infringed Patent Property. In the event that
the party not bringing the action does not want to participate in the recovery
obtained by settlement or otherwise, then the party instituting the law suit
shall be responsible for all costs and expenses of the non-participating party
in cooperating with the party instituting the law suit.

             7.3.       Infringement of Third Party Patent
Rights.

                           7.3.1    Joint Strategy.  In the event that the use or sale of a process or product incorporating
Dense Particle Cell Separation Technology in the CCTI Field and covered by the
Patent Property becomes the subject of a claim of infringement of a patent or
other proprietary right, the parties shall promptly confer to discuss the
claim.

                           7.3.2    Defense. Unless the parties otherwise agree, CCTI shall
assume the primary responsibility for the conduct of the defense of any such
claim described in Section 7.3.1. Coulter shall have the right, but not
the obligation, to participate in any such suit at its sole option and at its
own expense. Each party shall reasonably cooperate with the party conducting
the defense of the claim. No party shall enter into any settlement that affects
any other party's rights or interests without such other party's written
consent, not to be unreasonably withheld.

8.          TERM.

             This
Agreement shall continue in effect until the last to expire of any patents
within the Patent Property or the New Property Rights (as such term is defined
in Section 2.9) to which CCTI has exercised its option to a license or
sublicense, whether such patent is currently issued or issues from any patent
application contained within the Patent Property or the New Property Rights, or
for so long as CCTI is using a Biotechnology Asset.

9.          ASSIGNABILITY.

             Neither
this Agreement nor any part hereof shall be assignable by any party without the
prior, express, written permission of the other parties, which permission shall
not be unreasonably withheld. Any attempted assignment without such consent
shall be void. Notwithstanding the preceding two sentences, any party may
assign this Agreement in connection with the merger, consolidation, transfer or
sale of substantially all of its assets relating to the Property.

10.        NOTICES.

             All
notices required or permitted to be given under this Agreement shall be in
writing and shall be mailed by registered or certified mail, postage prepaid,
addressed to the signatory to whom such notice is required or permitted to be
given. All notices shall be deemed to have been given when mailed, as evidenced
by the postmark at the point of mailing.

	To
  Coulter:	 
	 	Wayne
  A. Barlin, Esq.

  Coulter Corporation

  11800 S.W. 147th Avenue

  Miami, Florida  33196
	 	 
	To
  CIC:	 
	 	Warren
  W. Kurz, Esq.

  Coulter International Corp.

  11800 S.W. 147th Avenue

  Miami, Florida  33196
	 	 
	To
  CCTI:	 
	 	Coulter
  Cellular Therapies, Inc.

  c/o InterWest Partners

  3000 Sand Hill Road

  Building 3

  Suite 225

  Menlo Park, California  94025

  Attention:  Dr. Arnold Oronsky
	 	 

 

Any party may, by written notice to the
others, designate a new addressee or address to which notices to the party
giving the notice shall thereafter be mailed.

11.        SEVERABILITY.

             If
a court of competent jurisdiction declares any provision of this Agreement
invalid or unenforceable, or if any government or other agency having
jurisdiction over either Coulter Corporation or CIC or CCTI deems any provision
to be contrary to any laws, then that provision shall be severed and the
remainder of the Agreement shall continue in full force and effect. To the
extent possible, the parties shall revise such invalidated provision in a
manner that will render such provision valid without impairing the parties'
original interests.

12.        ENTIRE
AGREEMENT.

             This
instrument contains the entire Agreement between the parties hereto. No verbal
agreement, conversation or representation between any officers, agents or
employees of the parties hereto either before or after the execution of this
Agreement shall affect or modify any of the terms or obligations herein
contained.

13.        MODIFICATIONS
IN WRITING.

             No
change, modification, extension, termination or waiver of this Agreement, or
any of the provisions herein contained, shall be valid unless made in writing
and signed by a duly authorized representative of each party.

14.        GOVERNING
LAW.

             The
validity and interpretation of this Agreement and the legal relations of the
parties to it shall be governed by the laws of the State of Delaware, excluding
Delaware's conflict of laws principles.

15.        CONSTRUCTION.

             The
parties agree that they have participated equally in the formation of this
Agreement and that the language herein should be not be presumptively construed
against any of them.

16.        ARBITRATION.

             16.1.    Any controversy or claim arising out of, or relating
to this Agreement shall be resolved by final and binding arbitration in
Chicago, Illinois under the Commercial Arbitration Rules of the American
Arbitration Association then obtaining.

             The
arbitration shall be subject to the following terms:

                           (a)         The number of arbitrators shall be three (3) unless
otherwise agreed to by the parties to the dispute.

                           (b)         The arbitrators shall be independent, impartial
third parties having no direct or indirect personal or financial relationship
to any of the parties to the dispute, who have agreed to accept the appointment
as arbitrators on the terms set forth in this Article 16.

                           (c)         The arbitrators shall be active or retired
attorneys, law professors, or judicial officers with at least five (5) years
experience in general commercial matters and a familiarity with the laws
governing proprietary rights in intellectual property.

                           (d)         The arbitrators shall be selected as follows:

                                        (i)         Each of Coulter Corporation and CCTI shall select
one arbitrator and these two arbitrators shall then agree on the selection of a
third arbitrator.

                                        (ii)        If the method of selection set out in Section
16.1(d)(i) fails for any reason, then either party may petition the United
States District Court for the Northern District of Illinois for appointment of
the arbitrators in accordance with applicable law, provided that the
arbitrators must satisfy the requirements of (b) and (c) above.

                           (e)         The arbitrators shall announce a decision in writing
accompanied by written findings explaining the facts determined in support of
the decision and any relevant conclusions of law.

                           (f)         Unless otherwise provided in this Article 16 or
extended by agreement of the parties, each of Coulter Corporation and CCTI
shall select an arbitrator within thirty (30) days after any request for
arbitration. The dispute shall be submitted to the three arbitrators within
ninety (90) days after they have been selected. A decision shall be rendered
within sixty (60) days after the dispute is submitted.

                           (g)        The fees of the arbitrators and any other costs and
fees associated with the arbitration shall be paid in accordance with the
decision of the arbitrators.

                           (h)        The arbitrators shall have no power to add to,
subtract from, or modify any of the terms or conditions of this Agreement. Any
decision rendered in such arbitration may be enforced by either party in the
United States District Court for the Northern District of Illinois, to whose
jurisdiction for such purposes the parties to the dispute hereby irrevocably
consent and submit.

             16.2.    Notwithstanding the foregoing, nothing in this
Article shall be construed to waive any rights or timely performance of any obligations
existing under this Agreement.

17.        FURTHER
ASSURANCES.

             Each
party agrees to furnish, upon request of one of the other parties to this
Agreement, such further information as may be required to give effect to the
transactions contemplated by this Agreement and to permit CCTI to fully enjoy
the benefit of the Property transferred hereunder. In the event a party makes a
good faith determination that it is necessary for the other parties to take
certain additional actions to give full effect to the transactions contemplated
by this Agreement and to permit CCTI to fully enjoy the benefit of the Property
transferred hereunder, such party shall notify the other parties of its
determination and the parties agree to meet to discuss in good faith the possibility
of such additional actions being taken.

18.        COUNTERPARTS.

             This
Agreement may be executed in one or more counterparts, each of which shall be
an original and all of which shall constitute together the same document.

             IN WITNESS
WHEREOF, the parties hereto have caused this License,
Assignment and Supply Agreement to be executed in triplicate by their duly
authorized representatives as of the dates noted below.

	 	COULTER
  CORPORATION
	 	 
	 	By:	 
	 	 	

	 	Title:	Executive
  Vice President
	 	Date:	February
  13, 1997
	 	 	 
	 	COULTER
  INTERNATIONAL CORP.
	 	 
	 	By:	/s/
  Warren W. Kurz
	 	 	

	 	Title:	Secretary/Corporate
  Patent Counsel
	 	Date:	February
  11, 1997
	 	 	 
	 	COULTER
  CELLULAR THERAPIES, INC.
	 	 
	 	By:	/s/
  Arnold Aronsky
	 	 	

	 	Title:	Chief
  Executive Officer
	 	Date:	February
  13, 1997

EXHIBIT 1

PATENT PROPERTY

             (a)         U.S.
PATENTS:

                                        (i)  U.S. PATENT NO. 5,576,185, (HEREINAFTER "THE
'l85 PATENT"), ISSUED NOVEMBER 19, 1996, ENTITLED "METHOD OF POSITIVE
OR NEGATIVE SELECTION OF A POPULATION OR SUBPOPULATION OF A SAMPLE UTILIZING
PARTICLES AND GRAVITY SEDIMENTATION."

                                        (ii)  U.S. PATENT NO. 5,466,609, (HEREINAFTER "THE
'609 PATENT"), ISSUED NOVEMBER 14, 1995, ENTITLED "BIODEGRADABLE
GELATIN-AMINNODEXTRAN PARTICLE COATINGS AND PROCESSES FOR MAKING SAME."

                                        (iii)  U.S. PATENT NO. 5,169,754, (HEREINAFTER "THE
'754 PATENT"), ISSUED DECEMBER 8, 1992, ENTITLED "BIODEGRADABLE
PARTICLE COATINGS HAVING A PROTEIN COVALENTLY IMMOBILIZED BY MEANS OF A
CROSSLINKING AGENT AND PROCESSES FOR MAKING SAME."

                                        (iv)  U.S. PATENT NO. 4,752,563, (HEREINAFTER "THE
'563 PATENT"), ISSUED JUNE 21, 1988, ENTITLED "MONOCLONAL ANTIBODY
FOR RECOVERY OF LEUKOCYTES IN HUMAN PERIPHERAL BLOOD AND METHOD OF RECOVERY
EMPLOYING SAID MONOCLONAL ANTIBODY."

                                        (v)  U.S. PATENT NO. 4,708,930, (HEREINAFTER "THE
'930 PATENT"), ISSUED NOVEMBER 24, 1987, ENTITLED "MONOCLONAL
ANTIBODY TO A HUMAN CARCINOMA TUMOR ASSOCIATED ANTIGEN."

                                        (vi)  U.S. PATENT NO. 4,865,971, (HEREINAFTER "THE
'971 PATENT"), ISSUED SEPTEMBER 12, 1989, ENTITLED "MONOCLONAL
ANTIBODY SPECIFIC TO A COMMON DETERMINANT SITE OF NEUTROPHILS AND
EOSINOPHILS."

             (b)         U.S.
PATENT APPLICATIONS:

                                        (i)  U.S. SERIAL NO. [**], FILED [**] (CONTINUATION OF
THE '185 PATENT) ENTITLED [**]

                                        (ii)  U.S. SERIAL NO. [**], FILED [**]
(CONTINUATION-IN-PART OF THE 1185 PATENT) ENTITLED [**]

                                        (iii)  U.S. SERIAL NO. [**], FILED [**], (DIVISIONAL OF
'609 PATENT), ENTITLED [**]

                                        (iv)  U.S. SERIAL NO. [**], FILED [**], (CONTINUATION OF
U.S. SERIAL NO. 08/961,157, WHICH IS A CONTINUATION-IN-PART OF THE '754
PATENT), ENTITLED [**]

             (c)         CORRESPONDING
FOREIGN PATENTS AND APPLICATIONS:

                                        (i)  INTERNATIONAL APPLICATION No. PCT/US96M7577, FILED
NOVEMBER 5, 1996, BASED ON USSN [**].

                                        (ii)  ARGENTINE SERIAL NO. 331-641, FILED APRIL 1, 1995,
BASED ON THE 85/PATENT.

                                        (iii)  AUSTRALIAN SERIAL NO. 24799/56, FILED APRIL 11,
1995, BASED ON THE 'l85 PATENT.

                                        (iv)  BRAZILIAN SERIAL NO. PI9507373.6, FILED APRIL 11,
1995, BASED ON THE '185 PATENT.

                                        (v)  CANADIAN SERIAL NO. (TO BE ASSIGNED), FILED APRIL
11, 1995, BASED ON THE '185 PATENT.

                                        (vi)  CHINESE SERIAL NO. 95192581.4, FILED APRIL 11, 1995,
BASED ON THE '185 PATENT.

                                        (vii)  COLOMBIAN SERIAL NO. 013,790, FILED APRIL 5, 1995,
BASED ON THE 'l85 PATENT.

                                        (viii)  EUROPEAN SERIAL NO. 95919112.3, FILED APRIL 11,
1995, BASED ON THE '185 PATENT.

                                        (ix)  ISRAEL SERIAL NO. 113,265, FILED APRIL 5, 1995,
BASED ON THE 'l85 PATENT.

                                        (x)  JAPANESE SERIAL NO. 7-527193, FILED APRIL 11, 1995,
BASED ON THE 'l85 PATENT.

                                        (xi)  MEXICAN SERJAL NO. 964,813, FILED APRIL 11, 1995,
BASED ON THE 'l85 PATENT.

                                        (xii)  NORWEGIAN SERIAL NO. P964,362, FILED APRIL 11, 1995,
BASED ON THE '185 PATENT.

                                        (xiii)  RUSSIAN SERIAL NO. 013,790, FILED APRIL 11, 1995,
BASED ON THE '185 PATENT.

                                        (xiv)  TAIWANESE SERIAL NO. 84103316, FILED APRIL 7, 1995,
BASED ON THE '185 PATENT.

                                        (xv)  VENEZUELAN SERIAL NO. 585/96, FILED APRIL 12, 1995,
BASED ON THE 'l85 PATENT.

                                        (xvi)  SOUTH AFRICAN SERIAL NO.95/2723, FILED APRIL 3,
1995, BASED ON THE '185 PATENT.

                                        (xvii)  CANADIAN SERIAL NO. 2146964, FILED OCTOBER 14, 1993,
BASED ON THE '609 PATENT.

                                        (xviii)  EUROPEAN SERIAL NO. 93923887, FILED OCTOBER 14,
1993, BASED ON THE '609 PATENT.

                                        (xix)  JAPANESE SERIAL NO. 51027/94, FILED OCTOBER 14,
1993, BASED ON THE '609 PATENT.

                                        (xx)  CANADIAN SERIAL NO. 2095148, FILED OCTOBER 25, 1991,
BASED ON THE '754 PATENT.

                                        xi)  EUROPEAN SERIAL NO. 92904811, FILED OCTOBER 25,
1991, BASED ON THE '754 PATENT.

                                        (xxii)  JAPANESE SERIAL NO. 505159/92, FILED OCTOBER 25,
1991, BASED ON THE '754 PATENT.

                                        (xxiii)  ARGENTINE PATENT NO. 235801, ISSUED OCTOBER 3, 1986,
BASED ON THE '563 PATENT.

                                        (xxiv)  AUSTRALIAN PATENT NO. 590615, ISSUED MARCH 8, 1990,
BASED ON THE '563 PATENT.

                                        (xxv)  BRAZILIAN APPLICATION NO. PCT P18606994, FILED
AUGUST 25, 1986, BASED ON THE '563 PATENT.

                                        (xxvi)  CANADIAN PATENT NO. 1294233, ISSUED JANUARY 14,
1992, BASED ON THE '563 PATENT.

                                        (xxvii)  GERMAN PATENT NO. P3685023.3, ISSUED APRIL 22, 1992,
BASED ON THE '563 PATENT.

                                        (xxviii)  SPANISH PATENT NO. 2001973, ISSUED MAY 27, 1988,
BASED ON THE '563 PATENT.

                                        (xxix)  FRENCH PATENT NO. 0245291, ISSUED APRIL 22, 1992,
BASED ON THE '563 PATENT.

                                        (xxx)  IRISH PATENT NO. 59433, ISSUED FEBRUARY 18, 1994,
BASED ON THE '563 PATENT.

                                        (xxxi)  ISRAEL PATENT NO. 80082, ISSUED MARCH 24, 1991,
BASED ON THE '563 PATENT.

                                        (xxxii)  ITALIAN PATENT NO. 0245291, ISSUED APRIL 22, 1992,
BASED ON THE '563 PATENT.

                                        (xxxiii)  JAPANESE APPLICATION NO. 504547/86, FILED AUGUST 25,
1986, BASED ON THE '563 PATENT.

                                        (xxxiv)  JAPANESE APPLICATION, DIVISIONAL OF 178276 (504547/86),
BASED ON THE '563 PATENT.

                                        (xxxv)  KOREAN APPLICATION NO. 700622/87, FILED AUGUST 25,
1986, BASED ON THE '563 PATENT.

                                        (xxxvi)  MEXICAN APPLICATION NO. 3792, FILED SEPTEMBER 22,
1986, BASED ON THE '563 PATENT.

                                        (xxxvii)  NORWEGIAN PATENT NO. I69243, ISSUED MAY 27, 1992,
BASED ON THE '563 PATENT.

                                        (xxxviii)  VENEZUELAN PATENT NO. 49397, ISSUED AUGUST 27, 1993,
BASED ON THE '563 PATENT.

                                        (xxxix)  SOUTH AFRICAN PATENT NO. 86/7150, ISSUED MAY 25,
1988, BASED ON THE '563 PATENT.

                                        (xl)  CANADIAN PATENT NO. 1243969, ISSUED NOVEMBER 1,
1988, BASED ON THE '930 PATENT.

                                        (xli)  ARGENTINE PATENT NO. 241656, ISSUED OCTOBER 30,
1992, BASED ON THE '971 PATENT.

                                        (xlii)  AUSTRIAN PATENT NO. 0371026, ISSUED APRIL 6, 1994,
BASED ON THE '971 PATENT.

                                        (xliii)  AUSTRALIAN PATENT NO. 618212, ISSUED APRIL 6, 1992,
BASED ON THE '971 PATENT.

                                        (xliv)  BELGIUM PATENT NO. 0371026, ISSUED APRIL 6, 1994,
BASED ON THE '971 PATENT.

                                        (xlv)  CANADIAN PATENT NO. 1297817, ISSUED MARCH 24, 1992,
BASED ON THE '971 PATENT.

                                        (xlvi)  SWISS PATENT NO. 0371026, ISSUED APRIL 6, 1994,
BASED ON THE '971 PATENT.

                                        (xlvii)  CHINESE PATENT NO. 88103992, ISSUED FEBRUARY 18,
1996, BASED ON THE '971 PATENT.

                                        (xlviii)  GERMAN PATENT NO. P3888971.4, ISSUED APRIL 6, 1994,
BASED ON THE  '971 PATENT.

                                        (xlix)  SPANISH PATENT NO. 2010761, ISSUED OCTOBER 3, 1989,
BASED ON THE '971 PATENT.

                                        (l)  FRENCH PATENT NO. 0371026, ISSUED APRIL 6, 1994,
BASED ON THE '971 PATENT.

                                        (li)  UNITED KINGDOM PATENT NO. 0371026, ISSUED APRIL 6,
1994, BASED ON THE '971 PATENT.

                                        (lii)  IRISH PATENT NO. 61554, ISSUED NOVEMBER 4, 1994,
BASED ON THE '971 PATENT.

                                        (liii)  ITALIAN PATENT NO. 0371026, ISSUED APRIL 6, 1994,
BASED ON THE '971 PATENT.

                                        (liv)  JAPANESE PATENT NO. 2579354, ISSUED NOVEMBER 7,
1996, BASED ON THE '971 PATENT.

                                        (lv)  SOUTH KOREAN APPLICATION NO. 700359/89, FILED
APRIL 25, 1988, BASED ON THE '971 PATENT.

                                        (lvi)  LUXEMBOURG PATENT NO. 0371026, ISSUED APRIL 6, 1994,
BASED ON THE '971 PATENT.

                                        (lvii)  MEXICAN PATENT NO. 175142, ISSUED JULY 8, 1994,
BASED ON THE '971 PATENT.

                                        (lviii)  NETHERLANDS PATENT NO. 0371026, ISSUED APRIL 6,
1994, BASED ON THE '971 PATENT.

                                        (lix)  NORWEGIAN PATENT NO. 176614, ISSUED MAY 3, 1995,
BASED ON THE '971 PATENT.

                                        (lx)  VENEZUELAN PATENT NO. 50.869, ISSUED JANUARY 17,
1994, BASED ON THE '971 PATENT.

                                        (lxi)  SOUTH AFRICAN PATENT NO. 88/3178, ISSUED JANUARY 31,
1990, BASED ON THE '971 PATENT.

             (d)         INVENTION
DISCLOSURE:

                                        (i)  CIC'S INVENTION DISCLOSURE 196,012 ENTITLED
"CELLULAR DEBRIS REMOVAL."Prepared by MERRILL CORPORATION

Exhibit
10.6

ASSUMED ELIGIX, INC

AMENDED AND RESTATED

MANAGEMENT EQUITY INCENTIVE PLAN

             Reference is hereby made to that
certain Management Equity Incentive Plan of Eligix, Inc. (the “Company”)
approved by the Board of Directors of the Company on May 25, 2000 (the
“Management Incentive Plan”).  The
purpose of the Management Incentive Plan is to provide the individuals listed
on Schedule A hereto (the “Participants,” and each, a “Participant”)
with an aggregate of 15% of the gross consideration received by the Company in
the event of a merger, reorganization, consolidation or similar business
transaction (a “Merger”) involving the Company and another entity, including
for this purpose BioTransplant Incorporated, a Delaware corporation (the
“Successor Company”).

             The Management Incentive Plan is
hereby amended and restated in its entirety as follows:

             The Participants shall be entitled
to an aggregate of 15% of the consideration received by the Company in a Merger
involving the Company and a Successor Company.  In the event that any portion of the consideration consists of
stock of the Successor Company (“Stock Consideration”), each such Participant’s
portion of the Stock Consideration shall be subject to the following vesting
schedule:

             a.          33
1/3% shall vest 90 days subsequent to the closing of the Merger;

             b.          another 33 1/3% shall vest 180 days subsequent to the
closing of the Merger;

             c.          another 23 1/3% shall vest 270 days subsequent to the
closing of the Merger; and

             d.          the final 10% shall vest 365 days subsequent to the closing
of the Merger;

provided,
however, that if such Participant is not offered employment with the Successor
Company or its affiliates other than the joint venture with Novartis, such
Participant’s portion of the Stock Consideration will vest upon closing of the
Merger; and further provided that if such Participant’s employment is
terminated by the Successor Company without “Cause” or by the Participant for
“good reason,” such Participant’s portion of the Stock Consideration will vest
upon such termination.  If any
Participant’s employment is terminated by the Successor Company for cause, or
by the Participant without good reason, the Successor Company may, but is not
required to, purchase any and all shares of such Participant’s portion of the
Stock Consideration that has not yet vested at a price of $.01 per share.  Such Participant’s portion of the Stock
Consideration will also be subject to any escrow arrangements applicable to the
holders of the Company’s capital stock in connection with the Merger.

             The Stock Consideration will become
immediately vested in the event of (i) any consolidation or merger of the
Successor Company with or into any other corporation, or any other corporate
reorganization, in which the stockholders of the Successor Company immediately
prior to such consolidation, merger or reorganization own less than 50% of the
voting power of the company succeeding the Successor Company immediately after
such consolidation, merger or reorganization; (ii) any transaction or series of
related transactions in which in excess of fifty percent (50%) of the Successor
Company’s voting power is transferred; (iii) a sale, lease or other disposition
of all or substantially all of the assets of the Successor Company; or (iv) any
sale or transfer of all or substantially all of those assets held by the
Company prior to the Merger.

             For purposes of this Management
Incentive Plan, “cause” shall mean (i) the willful (or grossly negligent) and
repeated neglect by the Participant of his or her reasonably assigned duties
with the Successor Company; provided such neglect remains uncured for a period
of thirty (30) days after written notice describing the same is given to the
Participant; and further provided, that the Participant is afforded an opportunity
to be heard on the matter by the Chief Executive Officer or the Board of
Directors of the Successor Company; (ii) the Participant’s conviction of any
felony or any other crime involving Successor Company funds, Successor Company
intellectual property or the theft of Successor Company funds, Successor
Company intellectual property or the theft of Successor Company property; (iii)
the breach by the Participant of any non-competition, non-solicitation,
confidentiality or comparable agreement with the Successor Company as
determined by a court of competent jurisdiction; or (iv) the Participant’s
habitual drunkenness, use of illegal substances or drugs or the habitual use,
possession, distribution or being under the influence of alcohol or illegal
substances or drugs in the workplace (the only exception is that the
Participant may consume alcohol reasonably and responsibly, if he or she so
chooses, at legitimate business events and functions where alcohol is legally
available).

             For purposes of this Management
Incentive Plan, “good reason” shall mean (i) any significant diminution,
without the Participant’s prior written consent, in the Participant’s duties,
responsibilities, power, title, or office; (ii) any material reduction in the
Participant’s compensation (including without limitation, salary, bonuses,
options and benefits) or material change in the manner of the Participant’s
compensation (including without limitation, the timing of any salary or bonus
payments) in effect on the date hereof or as the same may be increased during
the Participant’s employment; (iii) any requirement by the Successor Company or
any successor that the location at which the Participant is to perform the
Participant’s principal duties for the Successor Company or any successor be
outside a radius of fifty (50) miles from the location at which the Participant
had previously performed such duties immediately prior to the change of
location; or (iv) any breach by the Successor Company of any material provision
of this Management Incentive Plan or any other agreement between the Successor
Company and the Participant.

             It is hereby acknowledged and
agreed that all of the Participants are at-will employees, that nothing stated
in this Management Incentive Plan alters such status.  Accordingly, each such Participant’s employment may be terminated
by the Company, the Successor Company or the Participant at any time for any
reason and no such Participant is guaranteed employment for any specific period
of time.

             This Management Incentive Plan
shall be assumed by the Successor Company in any Merger.

             This Amendment and Restatement of
the Management Equity Incentive Plan shall become effective upon the Closing of
the Merger.

	 	Adopted by the

  Board of Directors

  on December 8, 2000

BioTransplant
Incorporated

Building 75, 3rd Avenue

Charlestown Navy Yard

Charlestown, MA  02129

Attn:    Elliot
Lebowitz

             Chief Executive Officer

Ladies
and Gentlemen:

             In connection with the closing of
the merger contemplated by the Agreement and Plan of Merger (the “Merger
Agreement”) dated as of December 8, 2000 among BioTransplant Incorporated
(“BTI”), Eligix, Inc. (“Eligix”) and the other parties thereto, certain members
of management of Eligix are to receive 990,000 shares of BTI Common Stock
pursuant to the Eligix Management Equity Incentive Plan (the “Plan”), as
previously adopted by Eligix on December 8, 2000.  In order to resolve any ambiguities in the operation of the Plan
resulting from (a) the resignation from Eligix of Cynthia Letizia and (b) David
Cook’s decision to join BTI as an employee for only a limited period of time
following the closing of the merger, each of which event has occurred following
the date of the Merger Agreement, we have agreed that the Plan shall be
implemented in accordance with the provisions of the Plan, the Merger Agreement
and the Escrow Agreement (as defined in the Merger Agreement), subject to the
following modifications:

             1.          The
percentage of shares initially allocated to Cynthia Letizia shall be
re-allocated among the remaining 11 initial Plan participants (the “Initial
Participants”) including, for this purpose, David Cook, on a weighted average
basis in accordance with the initial percentage interests of the Initial
Participants.

             2.          The
shares representing David Cook’s percentage participation in the Plan after
giving effect to the modifications set forth in paragraph 1 (102,414 shares,
hereinafter the “Cook Shares”) shall be treated as follows:

                           (a)         first, David Cook’s percentage interest
in the Plan shall be reduced to 34,135 shares in accordance with his offer
letter with BTI (the “Offer Letter Shares”); and

                           (b)        second, the remaining Cook Shares (less
the Offer Letter Shares) shall be distributed among the Initial Participants
(excluding, for this purpose, David Cook) on a weighted average basis in
accordance with the percentage interests of the Initial  Participants after giving effect to the
modifications in paragraph 1(as re-calculated, on a weighted average basis, to
exclude David Cook), and among certain other employees of Eligix who shall
become employees of BTI, in accordance with the Proceed Sharing Matrix attached
hereto (the “New Participants”).

             Giving effect to the foregoing
modifications, the allocation of percentages and shares for each of the Initial
Participants (including, for this purpose, David Cook) is as set forth on the
Proceed Sharing Matrix attached hereto.

             We have also agreed that
each of the New Participants, as a condition to his or her receipt of benefits
under the Plan in accordance with the terms of this letter, shall execute and
deliver to BTI, within ten (10) business days following the date hereof, a
counterpart signature page to the Escrow Agreement.

             Eligix represents and warrants to
BTI that Cynthia Letizia is not a Plan participant or eligible to receive any
equity under the Plan.  Eligix further
agrees that BTI may seek indemnification for any Damages (as defined in the
Merger Agreement) for breach of this representation in accordance with the indemnification
provisions of Article IV of the Merger Agreement and the provisions of the
Escrow Agreement.

             If you are in agreement with the
foregoing, please confirm this agreement by signing this document in the space
indicated below.

	 	 	Very truly yours,
	 	 	 
	 	 	/s/ Walter C. Ogier
	 	 	

	 	 	Walter C. Ogier
	 	 	Chief Executive
  Officer
	 	 	Eligix, Inc.
	 	 	 
	 	 	 
	Agreed and Accepted:	 	 
	 	 	 
	BioTransplant
  Incorporated	 	 
	 	 	 
	/s/
  Elliot Lebowitz	 	 
	

	 	 
	Elliot Lebowitz, Ph.D.	 	 
	Chief Executive
  Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]